Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Adaptive, Phase 2/3 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of INM004 in Pediatric Patients With Shiga Toxin-positive Bloody Diarrhea for Prevention of Hemolytic Uremic Syndrome

NCT04132375 is registered in ClinicalTrials.gov with Inmunova S.A. as lead sponsor.

NCT NCT04132375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04132375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Adaptive, Phase 2/3 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of INM004 in Pediatric Patients With Shiga Toxin-positive Bloody Diarrhea for Prevention of Hemolytic Uremic Syndrome
Lead sponsor
Inmunova S.A.
Phase
Phase 2/3
Overall status
Terminated
Start date
July 17, 2019
Completion date
July 19, 2022
Enrollment
11 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bloody diarrhea, hemolytic-uremic syndrome, pediatric kidney disease, stec, unspecified